236 related articles for article (PubMed ID: 24190964)
1. Platinum versus platinum-combination chemotherapy in platinum-sensitive recurrent ovarian cancer: a meta-analysis using individual patient data.
Raja FA; Counsell N; Colombo N; Pfisterer J; du Bois A; Parmar MK; Vergote IB; Gonzalez-Martin A; Alberts DS; Plante M; Torri V; Ledermann JA
Ann Oncol; 2013 Dec; 24(12):3028-34. PubMed ID: 24190964
[TBL] [Abstract][Full Text] [Related]
2. Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent or refractory ovarian cancer: a systematic review and economic evaluation.
Edwards SJ; Barton S; Thurgar E; Trevor N
Health Technol Assess; 2015 Jan; 19(7):1-480. PubMed ID: 25626481
[TBL] [Abstract][Full Text] [Related]
3. Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study.
Liu JF; Barry WT; Birrer M; Lee JM; Buckanovich RJ; Fleming GF; Rimel B; Buss MK; Nattam S; Hurteau J; Luo W; Quy P; Whalen C; Obermayer L; Lee H; Winer EP; Kohn EC; Ivy SP; Matulonis UA
Lancet Oncol; 2014 Oct; 15(11):1207-14. PubMed ID: 25218906
[TBL] [Abstract][Full Text] [Related]
4. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial.
Parmar MK; Ledermann JA; Colombo N; du Bois A; Delaloye JF; Kristensen GB; Wheeler S; Swart AM; Qian W; Torri V; Floriani I; Jayson G; Lamont A; Tropé C;
Lancet; 2003 Jun; 361(9375):2099-106. PubMed ID: 12826431
[TBL] [Abstract][Full Text] [Related]
5. A systematic overview of chemotherapy effects in ovarian cancer.
Högberg T; Glimelius B; Nygren P;
Acta Oncol; 2001; 40(2-3):340-60. PubMed ID: 11441940
[TBL] [Abstract][Full Text] [Related]
6. Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer.
Tattersall A; Ryan N; Wiggans AJ; Rogozińska E; Morrison J
Cochrane Database Syst Rev; 2022 Feb; 2(2):CD007929. PubMed ID: 35170751
[TBL] [Abstract][Full Text] [Related]
7. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
[TBL] [Abstract][Full Text] [Related]
8. Optimal chemotherapy treatment for women with recurrent ovarian cancer.
Fung-Kee-Fung M; Oliver T; Elit L; Oza A; Hirte HW; Bryson P
Curr Oncol; 2007 Oct; 14(5):195-208. PubMed ID: 17938703
[TBL] [Abstract][Full Text] [Related]
9. Platinum-containing regimens for metastatic breast cancer.
Egger SJ; Willson ML; Morgan J; Walker HS; Carrick S; Ghersi D; Wilcken N
Cochrane Database Syst Rev; 2017 Jun; 6(6):CD003374. PubMed ID: 28643430
[TBL] [Abstract][Full Text] [Related]
10. Management of platinum-sensitive recurrent ovarian cancer.
Pfisterer J; Ledermann JA
Semin Oncol; 2006 Apr; 33(2 Suppl 6):S12-6. PubMed ID: 16716798
[TBL] [Abstract][Full Text] [Related]
11. Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial.
Shi T; Zhu J; Feng Y; Tu D; Zhang Y; Zhang P; Jia H; Huang X; Cai Y; Yin S; Jiang R; Tian W; Gao W; Liu J; Yang H; Cheng X; Zang R
Lancet Oncol; 2021 Apr; 22(4):439-449. PubMed ID: 33705695
[TBL] [Abstract][Full Text] [Related]
12. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG.
Pfisterer J; Plante M; Vergote I; du Bois A; Hirte H; Lacave AJ; Wagner U; Stähle A; Stuart G; Kimmig R; Olbricht S; Le T; Emerich J; Kuhn W; Bentley J; Jackisch C; Lück HJ; Rochon J; Zimmermann AH; Eisenhauer E; ; ;
J Clin Oncol; 2006 Oct; 24(29):4699-707. PubMed ID: 16966687
[TBL] [Abstract][Full Text] [Related]
13. Treatment of recurrent ovarian cancer.
Pignata S; C Cecere S; Du Bois A; Harter P; Heitz F
Ann Oncol; 2017 Nov; 28(suppl_8):viii51-viii56. PubMed ID: 29232464
[TBL] [Abstract][Full Text] [Related]
14. Luteinising hormone releasing hormone (LHRH) agonists for the treatment of relapsed epithelial ovarian cancer.
Wuntakal R; Seshadri S; Montes A; Lane G
Cochrane Database Syst Rev; 2016 Jun; 2016(6):CD011322. PubMed ID: 27356090
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer.
Lawrie TA; Winter-Roach BA; Heus P; Kitchener HC
Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD004706. PubMed ID: 26676202
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer.
Winter-Roach BA; Kitchener HC; Dickinson HO
Cochrane Database Syst Rev; 2009 Jul; (3):CD004706. PubMed ID: 19588360
[TBL] [Abstract][Full Text] [Related]
17. Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer.
Patel A; Kalachand R; Busschots S; Doherty B; Kapros E; Lawlor D; Hall N; Stordal BK
Cochrane Database Syst Rev; 2022 Jul; 7(7):CD008766. PubMed ID: 35866378
[TBL] [Abstract][Full Text] [Related]
18. Pegylated liposomal doxorubicin for first-line treatment of epithelial ovarian cancer.
Lawrie TA; Rabbie R; Thoma C; Morrison J
Cochrane Database Syst Rev; 2013 Oct; 2013(10):CD010482. PubMed ID: 24142521
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapy in advanced ovarian carcinoma: current standards of care based on randomized trials.
Thigpen T; Vance R; Puneky L; Khansur T
Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S97-107. PubMed ID: 7835816
[TBL] [Abstract][Full Text] [Related]
20. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial.
Coleman RL; Brady MF; Herzog TJ; Sabbatini P; Armstrong DK; Walker JL; Kim BG; Fujiwara K; Tewari KS; O'Malley DM; Davidson SA; Rubin SC; DiSilvestro P; Basen-Engquist K; Huang H; Chan JK; Spirtos NM; Ashfaq R; Mannel RS
Lancet Oncol; 2017 Jun; 18(6):779-791. PubMed ID: 28438473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
